Suggested remit: To appraise the clinical and cost effectiveness of evinacumab within its marketing authorisation for treating homozygous familial hypercholesterolaemia in people aged 12 and over.
Status Proposed
Process STA 2018
ID number 2704

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
14 September 2020 (14:00) Scoping workshop
16 July 2020 - 13 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance